| 000 | 00951 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250517065442.0 | ||
| 264 | 0 | _c20160624 | |
| 008 | 201606s 0 0 eng d | ||
| 022 | _a1750-7448 | ||
| 024 | 7 |
_a10.2217/imt.15.95 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFajgenbaum, David C | |
| 245 | 0 | 0 |
_aSiltuximab: a targeted therapy for idiopathic multicentric Castleman disease. _h[electronic resource] |
| 260 |
_bImmunotherapy _c2016 |
||
| 300 |
_a17-26 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aBiomarkers |
| 650 | 0 | 4 |
_aCastleman Disease _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 |
_aInterleukin-6 _ximmunology |
| 700 | 1 | _aKurzrock, Razelle | |
| 773 | 0 |
_tImmunotherapy _gvol. 8 _gno. 1 _gp. 17-26 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/imt.15.95 _zAvailable from publisher's website |
| 999 |
_c25511841 _d25511841 |
||